Abstracts & Posters 2025

O1 Autologous neutralising antibodies and effective CD8 T-cells maintain long-term HIV-1 post-intervention control
Katie Fisher et al.
O2 High intestinal fatty acid binding protein (I-FABP) predicts slow CD4 recovery in immunological non-responders of HIV
Hanne Hestdal Gullaksen et al.
O3 Trends in late HIV diagnosis and its association with education and income: a nationwide cohort study from 2003 to 2023 in Sweden
Sara Falk et al.
O4 Predictors of Critical Illness During Different COVID-19 Pandemic Phases Compared to Seasonal Influenza
Josefine Beck-Friis et al.
O5 Virological and biochemical responses of combination treatment with bulevirtide and pegylated-interferon up to w72 in CHD: results from SEE-D trial
Habiba Kamal et al.
O6 Immunomodulatory imide drugs (IMiDs) reinvigorate anti-HBV immunity ex vivo.
Rachel Pascoe et al.
P1 HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant from CCR5Δ32/Δ32 Sibling Donor
Hanne Hestdal Gullaksen et al. Complete documentation
P2 High Risk of Renal Outcomes After Type 2 Diabetes Mellitus in People with HIV vs without HIV: Findings From the Cohort Study on Morbidity and HIV in Sweden
Isabela Killander Möller et al. Complete documentation
P3 Biomarkers of neuronal injury and neuroinflammation after switching to dolutegravir/lamivudine in people with HIV
Linn Renborg et al. Complete documentation
P4 CD4 Cell Count Trends After The Most Common Cancers in People With HIV: A Multicohort Collaboration
Alisa Timiryasova et al. Complete documentation
P5 Risk of Income Loss in People Living With and Without HIV – a Comparative Swedish Nationwide Study Between 2019 to 2021
Isabella Killander Möller et al. Complete documentation
P6 Hypergammaglobulinemia in treated and untreated people with HIV
Isabel Vigmo et al.
P7 No association between plasma homocysteine and amyloid metabolism in people living with HIV
Julia Kempa et al. Complete documentation
P8 Effectiveness of mobile wireless technologies interventions for the prevention of vertical transmission: A systematic review and meta-analysis
Winfred Mwangi et al. Complete documentation
P9 Clinical characteristics and reasons for switching to long-acting cabotegravir + rilpivirine in routine care: Insights from the Nordic VALHALLA study
Liisa Lehtoranta et al. Complete documentation
P10 Getting Steamy: Nurse-Led Sexual Health Services for Priority Populations: 40 Years of Innovation at WAAC in Western Australia
Garry Kuchel et al. Complete documentation
P11 Evaluation of blood sampling with standardised filter paper technology for commercial molecular and serological analysis of hepatitis B-, C and HIV
Anna Maria Delis et al. Complete documentation
P12 Risk of Long COVID Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis
Julia Fonseca de Morais Caporali et al. Complete documentation
P13 The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: emulated target trial
John Karlsson Valik et al. Complete documentation
P14 Good flare or bad flare? ALT variability predicts outcome after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
Marte Holmberg et al. Complete documentation
P15 Toward Hepatitis C Elimination in Denmark: We “C” a Major Prevalence Decline, but Remaining Gaps to Reach WHO 2030 Goals Exist
Signe Freja Storgaard et al. Complete documentation
P16 Long-term risk for hepatocellular carcinoma in 1,167 African-born patients with chronic hepatitis B living in Sweden
Katarina Johansson Århem et al. Complete documentation
P17 Limited value of repeated quantitative HBsAg for clinical management of chronic HBV infection – stability over time and impact on reactivation risk
Catharina Alexandersson et al. Complete documentation
P18 Pomalidomide as an immune-enhancing agent to control HIV
Maya Dyveke Schou et al. Complete documentation